We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+7.36%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$496M
AUM Growth
+$20M
(+4.2%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
3.33%
Top 10 Holdings %
Top 10 Hldgs %
30.96%
Holding
92
New
31
Increased
21
Reduced
18
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$13.3M |
| 2 |
Elevance Health
ELV
|
+$12.4M |
| 3 |
Revvity
RVTY
|
+$11.2M |
| 4 |
Biogen
BIIB
|
+$11.1M |
| 5 |
Humana
HUM
|
+$9.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$15.6M |
| 2 |
Cigna
CI
|
+$14.9M |
| 3 |
Universal Health Services
UHS
|
+$14.1M |
| 4 |
Intuitive Surgical
ISRG
|
+$11.7M |
| 5 |
Moderna
MRNA
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.57% |
| 2 | Consumer Staples | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
51
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $3.52M | 0.71% |
152,000
-23,000
| -13% | -$548K |
|
|
FOLD
52
DELISTED
Amicus Therapeutics
FOLD
| $3.38M | 0.68% |
305,000
-22,000
| -7% | -$271K |
|
|
CTLT
53
DELISTED
CATALENT, INC.
CTLT
| $3.29M | 0.66% |
+50,000
| New | +$3.09M |
|
|
RXDX
54
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $3.22M | 0.65% |
30,000
+10,000
| +50% | +$1.15M |
|
55
Option Care Health
OPCH
$3.61B
| $3.21M | 0.65% |
+101,000
| New | +$3.03M |
|
|
AKRO
56
DELISTED
Akero Therapeutics
AKRO
| $2.68M | 0.54% |
70,000
| – | – |
|
57
Regeneron Pharmaceuticals
REGN
$82.1B
| $2.47M | 0.5% |
+3,000
| New | +$2.26M |
|
|
ITOS
58
DELISTED
iTeos Therapeutics
ITOS
| $2.45M | 0.49% |
180,000
-90,000
| -33% | -$1.61M |
|
|
LBPH
59
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $2.33M | 0.47% |
582,000
+339,000
| +140% | +$1.66M |
|
60
Keros Therapeutics
KROS
$211M
| $2.13M | 0.43% |
50,000
-10,000
| -17% | -$505K |
|
61
CALL
Aclaris Therapeutics
ACRS
$871M
| $2.02M | 0.41% |
+250,000
| New | +$3.17M |
|
62
Allogene Therapeutics
ALLO
$732M
| $2M | 0.4% |
+405,000
| New | +$2.6M |
|
63
SkinHealth Systems
SKIN
$91.1M
| $1.92M | 0.39% |
+152,000
| New | +$1.76M |
|
|
KYNB
64
Kyntra Bio
KYNB
$28.6M
| $1.9M | 0.38% |
4,080
-2,920
| -42% | -$1.54M |
|
|
MRUS
65
CALL
DELISTED
Merus
MRUS
| $1.84M | 0.37% |
+100,000
| New | +$1.74M |
|
|
66
Aclaris Therapeutics
ACRS
$871M
| $1.82M | 0.37% |
225,000
-145,000
| -39% | -$1.84M |
|
67
GoodRx Holdings
GDRX
$1.3B
| $1.27M | 0.26% |
+203,000
| New | +$1.13M |
|
|
TERN
68
DELISTED
Terns Pharmaceuticals
TERN
| $1.18M | 0.24% |
+100,000
| New | +$956K |
|
|
NUVL
69
PUT
DELISTED
Nuvalent
NUVL
| $913K | 0.18% |
+35,000
| New | +$1.04M |
|
|
EXAI
70
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $806K | 0.16% |
+152,000
| New | +$1.03M |
|
71
Dyne Therapeutics
DYN
$4.99B
| $657K | 0.13% |
+57,000
| New | +$740K |
|
72
AstraZeneca
AZN
$246B
| – | – |
-70,000
| Closed | -$9.49M |
|
|
73
Cigna
CI
$72.4B
| – | – |
-45,000
| Closed | -$14.9M |
|
74
Centene
CNC
$32.1B
| – | – |
-100,000
| Closed | -$8.2M |
|
75
CALL
Cytokinetics
CYTK
$10.6B
| – | – |
-400,000
| Closed | -$18.3M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, Integral Health Asset Management held 92 positions worth $496M, up 4.2% from $476M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Integral Health Asset Management deployed $16.5M of net new capital in Q1 2023, opening 31 new positions and adding to 21 existing holdings. Its largest new stake was Stryker: 50,000 shares worth $14.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 93% a quarter earlier, followed by Consumer Staples.
On the sell side, the largest reduction was Moderna, an estimated $10.7M trimmed.
- Integral Health Asset Management's largest Q1 2023 buy was Stryker: 50,000 shares worth $14.3M.
- Integral Health Asset Management added most to Elevance Health in Q1 2023, an estimated $12.4M increase.
- Integral Health Asset Management's biggest Q1 2023 reduction was Moderna, cutting an estimated $10.7M.
- Integral Health Asset Management fully exited Quest Diagnostics in Q1 2023, selling an estimated $15.6M.
- Integral Health Asset Management's ten largest holdings make up 31% of its $496M portfolio in Q1 2023.
- Integral Health Asset Management opened 31 new positions and closed 21 in Q1 2023.
- Integral Health Asset Management's portfolio value rose 4.2% quarter-over-quarter to $496M.
Based on Integral Health Asset Management's 13F filing for Q1 2023, filed 9 May 2023.